Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Figma Inc. Class A Common Stock (FIG) vs Novavax Inc (NVAX) Price & Performance

Figma Inc. Class A Common StockTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

Figma Inc. Class A Common Stock vs Novavax Inc — how do they compare? Figma Inc. Class A Common Stock trades at $21.33 (market cap $11.45B), while Novavax Inc trades at $12.41 (market cap $2.11B). The key difference: Figma Inc. Class A Common Stock is far larger — about 5.4× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Figma Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Figma Inc. Class A Common Stock for 0 Days and Novavax Inc for 59 Days on average.

FIGNVAX
Market Cap
$11.45B$2.11B
Volume
12,424,8938,376,831
Sector
TechnologyHealth
52-Week High
$63.82$12.82
52-Week Low
$16.84$6.22
Typical Hold Time
0 Days59 Days
Enterprise Value
$9.85B$1.69B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Figma Inc. Class A Common Stock

No Aura AI signal available yet.

Novavax Inc

Novavax (NVAX) trades at $12.82, up 1.26% on the day, with a bullish technical signal and strong analyst support. Recent earnings beats and strategic pivots toward its Matrix-M adjuvant platform and partnerships, such as with Sanofi for COVID-19 vaccines, highlight operational progress. However, negative cash flows and a net loss in 2026 projections underscore financial volatility amid transitioning revenue streams.

The outlook balances near-term catalysts from vaccine approvals and partnership momentum against persistent cash burn and competitive pressures. Investors face opportunity in undervalued metrics like a low P/E of 3.14, but risks include execution hurdles and dependency on successful licensing deals to achieve sustainable profitability.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

FIG
100% Buy0% Sell
Avg holding period · 0 Days
NVAX
28% Buy72% Sell
Avg holding period · 59 Days

About Figma Inc. Class A Common Stock

Figma, Inc. is a US software company that operates a collaborative interface design and product development platform used by design and engineering teams to create, prototype, and build digital products.

Read more on FIG →

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX →